Condor’s announcement comes as looming patent cliffs across the pharmaceutical industry intensify pressure on companies to replenish their pipelines. While AI has accelerated drug discovery and increased the number of viable candidates, the financial infrastructure drug development runs on remains remarkably manual and labor intensive. When a budget, forecast, and actuals diverge, R&D teams can lose hours, if not days, reconciling data across ERPs, CTMS, EDC systems, and spreadsheets to better understand the financial impact behind the “why”. Lagging decisions have real consequences — like continuing to fund an underperforming site, discovering a change-order problem after negotiations are already underway, or waiting weeks to understand the financial implications of an enrollment change.
The clinical finance agent reasons across an organization’s full budget and forecast history in Condor to explain the “why” behind the numbers, identifying in seconds rather than hours what’s driving a variance between actuals and forecast or the cost to complete a given trial. It also runs full what-if scenario planning, modeling changes to site mix, enrollment timing, or financial investment, and then builds the resulting model directly in the platform. Powered by Condor’s proprietary knowledge graph and a deterministic math layer with AI reasoning on top, the agent is tuned to how R&D teams actually ask questions; not generic corporate forecasting logic. Additionally capabilities will be added to the agent soon.
Here’s how the agent works: you ask the questions that used to take your team weeks to prepare, and instantly get answers you can act on. For example, an R&D team’s clinical operations or finance leader can ask:
“Which sites in this trial are falling behind, and what does that mean for my budget, timeline, and enrollment?” Condor identifies the sites creating risk and connects their performance to the downstream impact on enrollment, timing, and cost.
“What will it cost to complete enrollment?” Condor calculates a cost-to-complete forecast based on the current state of the trial, without waiting weeks for a team to manually rebuild the model.
“Why did my change order increase?” Condor traces the increase back to the clinical and operational activity driving it and identifies where there may be an opportunity to reduce the cost.
To see the agent in action, book a demo at https://condorsoftware.com/contact.
The clinical finance agent is one of several agents in Condor AI Workflows — one of Condor’s three product pillars. Condor Connect automatically centralizes clinical, operational, and financial data with an understanding of a biopharma’s processes. Condor AI Workflows then automates various workflows — like budgeting, forecasts, month-end closes, accruals, and change order management. Condor AI Insights then surfaces patterns, flags risks, bridges context across functions, and delivers the “why” behind the numbers.
Supporting Quotes
“Drug development runs on two things: the science and the money that funds it. For decades, science was the bottleneck. AI and the patent cliff are closing that gap, and pipelines are about to fill with more candidates than this industry has ever had to fund. But the bottleneck didn’t disappear. It moved from the lab to the ledger. Every one of those candidates still has to be forecasted, funded, and managed, and the financial infrastructure doing that job still runs on spreadsheets. The pharmaceutical industry doesn’t have a data problem. It has a context problem. Companies have more data than they’ve ever had. But answering a basic question like ‘Why did this trial get more expensive?’ can still require people to hunt across multiple systems and rebuild the answer manually. We started Condor to eliminate that gap, and our new clinical finance agent takes us one huge step closer to realizing our mission of giving biopharma R&D teams the information they need to make clinical and financial decisions quickly and confidently.”
—Condor Founder and CEO Jen Kyle
“Quickly producing the ‘why’ behind the numbers is the biggest pain point that clinical operations and FP&A teams experience. Any system can tell you you’re five million over budget. That’s not useful on its own. You need to know in a clinical context what’s actually driving it, and you need to know fast. Our knowledge graph lets us answer that in a way generic AI can’t, because it intimately understands the context underpinning the clinical trial activities. And it doesn’t stop at the answer; it also builds the model. Our clinical finance agent is one of many Condor AI agents, each purpose-built to remove a specific piece of the manual work that slows R&D teams down.”
— Condor VP of Product Nim Fox
About Condor Software
Condor Software is the AI platform for biopharma R&D teams. It automatically centralizes clinical, operational, and financial data; automates various workflows — like budgeting, forecasts, month-end closes, accruals, and change order management; and then surfaces patterns, flags risks, bridges context across functions, and delivers the “why” behind the numbers. Founded by Jen Kyle, Condor is backed by Insight Partners, Felicis, 645 Ventures, Pamir Ventures, and SNR Ventures, and is trusted by leading biopharma companies worldwide — including Acadia Pharmaceuticals, BridgeBio Pharma, Madrigal Pharmaceuticals, and Stemline Therapeutics. Learn more at condorsoftware.com.
Media Contact:
Joseph Roualdes
[email protected]
415.823.2136
SOURCE Condor Software
